Essential Planning LLC. Makes New Investment in OPKO Health, Inc. (NASDAQ:OPK)

Essential Planning LLC. bought a new position in shares of OPKO Health, Inc. (NASDAQ:OPK) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 331,175 shares of the biotechnology company’s stock, valued at approximately $506,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in OPK. Intech Investment Management LLC purchased a new stake in shares of OPKO Health in the third quarter worth about $190,000. Integrated Investment Consultants LLC purchased a new stake in shares of OPKO Health in the third quarter worth about $233,000. FMR LLC lifted its holdings in shares of OPKO Health by 103.6% in the third quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock worth $32,000 after buying an additional 11,089 shares in the last quarter. BNP Paribas Financial Markets lifted its holdings in shares of OPKO Health by 736.7% in the third quarter. BNP Paribas Financial Markets now owns 246,967 shares of the biotechnology company’s stock worth $368,000 after buying an additional 217,450 shares in the last quarter. Finally, Rubric Capital Management LP lifted its holdings in shares of OPKO Health by 9.6% in the third quarter. Rubric Capital Management LP now owns 48,706,640 shares of the biotechnology company’s stock worth $72,573,000 after buying an additional 4,284,336 shares in the last quarter. Institutional investors own 64.63% of the company’s stock.

Analyst Ratings Changes

OPK has been the topic of a number of recent analyst reports. StockNews.com raised shares of OPKO Health from a “sell” rating to a “hold” rating in a report on Monday, March 3rd. Barrington Research reaffirmed an “outperform” rating and issued a $2.25 target price on shares of OPKO Health in a research note on Wednesday. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $3.00 target price on shares of OPKO Health in a research note on Wednesday.

Insiders Place Their Bets

In other OPKO Health news, CEO Phillip Md Et Al Frost purchased 67,434 shares of the firm’s stock in a transaction on Friday, February 28th. The shares were purchased at an average cost of $1.71 per share, with a total value of $115,312.14. Following the completion of the purchase, the chief executive officer now owns 213,301,448 shares of the company’s stock, valued at $364,745,476.08. The trade was a 0.03 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Over the last ninety days, insiders have acquired 764,971 shares of company stock valued at $1,145,692. 47.26% of the stock is currently owned by corporate insiders.

OPKO Health Trading Down 3.4 %

Shares of OPK opened at $1.72 on Friday. The firm’s 50 day simple moving average is $1.61 and its 200 day simple moving average is $1.57. The company has a market capitalization of $1.16 billion, a P/E ratio of -9.05 and a beta of 1.70. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69. OPKO Health, Inc. has a 1-year low of $0.86 and a 1-year high of $2.04.

OPKO Health (NASDAQ:OPK) last announced its earnings results on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.09. The business had revenue of $183.60 million for the quarter, compared to the consensus estimate of $155.42 million. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. Sell-side analysts forecast that OPKO Health, Inc. will post -0.25 earnings per share for the current fiscal year.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.